Ontrak, Inc.

  • Market Cap: Micro Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US6833733024
USD
0.00
0.00 (0.00%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryCompany CV
About Ontrak, Inc. stock-summary
stock-summary
Ontrak, Inc.
Pharmaceuticals & Biotechnology
Ontrak, Inc., formerly Catasys, Inc., is an artificial intelligence (AI)-powered and telehealth-enabled, virtualized outpatient healthcare treatment company. Its Ontrak PRE (Predict-Recommend-Engage) platform predicts people whose chronic disease will improve with behavior change, recommends care pathways that people are willing to follow, and engages people who aren’t getting the care they need. The Company’s integrated, technology-enabled OnTrak solution, which is designed to identify and treat members with behavioral conditions that cause or exacerbate chronic medical conditions such as diabetes, hypertension, coronary artery disease, chronic obstructive pulmonary disease, and congestive heart failure. OnTrak integrates evidence-based psychosocial and medical interventions delivered either in-person or via telehealth, along with care coaching and in-market Community Care Coordinators who address the social and environmental determinants of health, including loneliness.
Company Coordinates stock-summary
Company Details
2120 COLORADO AVE, SUITE 230 , SANTA MONICA CA : 90404
stock-summary
Tel: 1 310 44443001 310 444-4346
stock-summary
Registrar Details
stock-recommendation Shareholding
Shareholding Snapshotstock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 2 Schemes (0.56%)

Foreign Institutions

Held by 5 Foreign Institutions (0.06%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summary Board of Directorsstock-summary
Management
Designation
Mr. Terren Peizer
Chairman of the Board, Chief Executive Officer, Director
Ms. Katherine Quinn
Director
Mr. Richard Berman
Independent Director
Mr. Gustavo Giraldo
Independent Director
Mr. Robert Rebak
Independent Director
Ms. Diane Seloff
Independent Director
stock-recommendation Stock DNA
Revenue and Profits:
Net Sales:
2 Million
(Quarterly Results - Mar 2025)
Net Profit:
-7 Million
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 0 Million (Micro Cap)

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

1.19

stock-summary
Return on Equity

-601.03%

stock-summary
Price to Book

0.02